Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,973.00
Bid: 1,972.00
Ask: 1,974.00
Change: -4.00 (-0.20%)
Spread: 2.00 (0.101%)
Open: 1,951.00
High: 1,980.00
Low: 1,951.00
Prev. Close: 1,977.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 28th Feb 2013 07:19

AZ Electronic Materials: Goldman Sachs moves target price from 440p to 450p and retains a buy recommendation.Bovis Homes Group: Deutsche Bank shifts target price from 667p to 679p, while downgrading to hold.British American Tabacco: Investec places its target price (previously 3350p) and buy recommendation under review.Croda International: Goldman Sachs raises target price from 3150p to 3200p still recommending strong buying.Elementis: Goldman Sachs revises target price from 255p to 265p, while its neutral rating remains unchanged.Eurasian Natural Resources: Deutsche Bank lowers target price from 562p to 550p and stays with its buy recommendation.Genel Energy: Investec reduces target price from 1104p to 1000p keeping its buy recommendation.Gooch & Housego: N+1 Singer raises target price from 470p to 515p and upgrades to buy.Hays: Jefferies takes target price from 105p to 115p and reiterates its buy recommendation.Henderson Group: Morgan Stanley cuts target price from 160p to 154p, while retaining an equal-weight rating. UBS downgrades to neutral with a target price of 158p. Barclays lowers target price from 153p to 145p and reiterates an underweight rating. JP Morgan raises target price from 162p to 183p and maintains its neutral rating.Hikma: Panmure Gordon raises target price from 825p to 930p, while staying with its buy recommendation.Interserve: JP Morgan increases target price from 466p to 532p reiterating an overweight rating.Intu Properties: Jefferies lowers target price from 335p to 310p maintaining a hold recommendation. Deutsche Bank reduces target price from 480p to 410p and keeps its buy rating.ITV: Deutsche Bank ups target price from 90p to 100p, but still recommends selling. UBS raises target price from 90p to 115p and retains an equal-weight rating. Westhouse Securities increases target price from 133p to 141p and upgrades from add to buy. Investec shifts target price from 100p to 110p and upgrades from sell to hold. JP Morgan shifts target price from 120p to 126p, while its neutral rating remains unchanged. Panmure Gordon ups target price from 140p to 180p leaving its buy recommendation unaltered.LSL Property Services: Panmure Gordon ups target price from 287p to 337p and retains a buy recommendation.Petrofac: Morgan Stanley reduces target price from 2300p to 2100p, while leaving its overweight rating unchanged. Nomura downgrades target price from 1830p to 1740p reiterating a buy recommendation. Barclays cuts target price from 1900p to 1800p and reiterates an underweight rating.Promethean: JP Morgan shifts target price from 20p to 22p and leaves its neutral rating unchanged.Restaurant Group: Barclays takes target price from 400p to 460p, while staying with its overweight rating.Segro: Jefferies moves target price from 228p to 238p and keeps a hold recommendation.Severfield-Rowen: Canaccord Genuity reduces target price from 50p to 37p, while its sell recommendation is kept.Shire: Nomura cuts target price from 2300p to 2160p and downgrades from buy to neutral.Spirent Communications: Canaccord Genuity reduces target price from 180p to 156p downgrading from buy to hold. Panmure Gordon shifts target price from 192p to 191p and reiterates a buy recommendation.Standard Life: Credit Suisse shifts target price from 315p to 321p and keeps its underperform rating.St. James's Place: Investec places its target price (previously 472p) and buy recommendation under review.Synthomer: Goldman Sachs raises target price from 195p to 230p, while maintaining a neutral rating.United Carpets: After having had its target price under review, Cantor Fitzgerald places it at 2.5p and retains a hold recommendation.Victrex: Goldman Sachs increases target price from 1775p to 1850p reiterating a buy rating.Vitec Group: Investec moves target price from 700p to 740p and retains a buy recommendation.Weir Group: JP Morgan raises target price from 2500p to 2600p, while its overweight rating remains unchanged.Whitbread: Nomura ups target price from 2650p to 2968p and leaves its buy recommendation unaltered.Xchanging: Cantor Fitzgerald raises target price from 120p to 145p upgrading from hold to buy.
More News
24 Feb 2022 10:31

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.

Read more
24 Feb 2022 07:58

Hikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'

(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.

Read more
24 Feb 2022 07:50

LONDON MARKET PRE-OPEN: Share buybacks for Lloyds Banking and Hikma

(Alliance News) - Stock prices in London are seen opening sharply lower, with the FTSE 100 called down almost 200 points, amid fear of a full-scale war in eastern Europe after Russia announced the beginning of a military operation in Ukraine.

Read more
17 Feb 2022 16:08

UK earnings, trading statements calendar - next 7 days

Friday 18 February  
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 21 February 
Bank of Cyprus Holdings PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Tristel PLCTrading Statement
Wilmington PLCHalf Year Results
Tuesday 22 February 
Antofagasta PLCFull Year Results
Bank of Georgia Group PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Blancco Technology Group PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Coca-Cola HBC AGFull Year Results
Hargreaves Lansdown PLCHalf Year Results
HSBC Holdings PLCFull Year Results (at 0400 GMT)
InterContinental Hotels Group PLCFull Year Results
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Synectics PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wednesday 23 February 
Aston Martin Lagonda Global Holdings PLCFull Year Results
Barclays PLCFull Year Results
Capital & Counties Properties PLCFull Year Results
CAP-XX LtdHalf Year Results
Georgia Capital PLCFull Year Results
International Personal Finance PLCFull Year Results
Irish Residential Properties REIT PLCFull Year Results
Metro Bank PLCFull Year Results
Hochschild Mining PLCFull Year Results
Photo-Me International PLCFull Year Results
Rio Tinto PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCFull Year Results
Thursday 24 February 
Anglo American PLCFull Year Results
BAE Systems PLCFull Year Results
Centrica PLCFull Year Results
Conduit Holdings LtdFull Year Results
Derwent London PLCFull Year Results
Drax Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Inchcape PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Rathbone Group PLCFull Year Results
Ricardo PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
St James's Place PLCFull Year Results
Tremor International LtdFull Year Results
WPP PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.